Douglas Paul Clark, MD

Physician, pathologist, and healthcare executive. Transforming pathology and medicine with technology.

[Douglas Paul Clark, MD @futurepathology]

I'm excited to moderate this unique seminar at the upcoming #USCAP2022 meeting where practicing pathologists will demonstrate how they utilize @IbexMedAx #AI-based products to resolve challenging cases in their diagnostic #pathology practice.

[Douglas Paul Clark, MD @futurepathology]

I'm very excited to moderate this star-studded @IbexMedAx seminar at the upcoming #USCAP2022 meeting, where these world-renowned pathologists will share their visions for the future of #AI in #pathology

[Douglas Paul Clark, MD @futurepathology]

@dpatweet @Aparwani_dpath @Visiopharm I'm so proud to be part of the leadership of this innovative organization aimed at improving patient outcomes through digital pathology and AI. Please join @dpatweet and encourage all your trainees to engage!

[Douglas Paul Clark, MD @futurepathology]

I am delighted to announce that I have recently joined Ibex Medical Analytics as their Chief Medical Officer for the Americas. Excited to work with the @IbexMedAx team to provide #pathologists with #AI based tools to improve cancer diagnostics and enhance patient outcomes.

[Douglas Paul Clark, MD @futurepathology]

These shortages revealed the complexity and fragility of lab testing due to dependency on worldwide sourcing of multiple components for a single test (swabs, media, pipette tips, etc.). Solutions for the next pandemic?

[nature @Nature]

Shortfalls of gloves, micropipettes, pipette tips and other supplies are expected to last for the “duration of the COVID-19 public health emergency”. https://t.co/YgjFYVEMza

[Douglas Paul Clark, MD @futurepathology]

@01sth02 Agree. Please don’t put my H-score or “years of continuous NIH funding” on my tombstone.

[Douglas Paul Clark, MD @futurepathology]

Nanobodies: interesting antibodies from camelids
-heavy chains only with a single variable domain and two constant domains.
-First diagnostic applications?
-Why camelids?
Neuroscientists isolate promising mini antibodies against COVID-19 from a llama https://t.co/a0yotQvoaT

[Douglas Paul Clark, MD @futurepathology]

Sloppy journalism. From Facebook post to ABC News. The story confirms it's not a story.
Vaccinated U.S. nurse contracts COVID-19, expert says Pfizer shot needed more time to work - ABC https://t.co/IFcaGDoPJv

[Douglas Paul Clark, MD @futurepathology]

Hype. COVID viral loads are a "rough approximation" because of sample and clinical variability and lack of standardization.
-association is not a prognostic test
-"more virus is generally not good"
You’re Infected With the Coronavirus. But How Infected? https://t.co/kacesSHN8V

[Douglas Paul Clark, MD @futurepathology]

@michaelmina_lab Unfortunately, distribution and utilization of rapid tests will likely be unevenly distributed across different cultural and socioeconomic subpopulations, with access and compliance lowest in the neediest groups. What would less idealized models show?

[Douglas Paul Clark, MD @futurepathology]

@ktmontone @PennMedicine @PennPathLabMed @aakasharmand @feldmanm30 @david_b_roth2 I'll greatly miss my friend and mentor. Prabodh made cytopathology exciting through his experience, his stories, and his personality. His stories at the microscope started with "let me tell you.." And we listened.

[Douglas Paul Clark, MD @futurepathology]

@cytopathology @pambuccian @loyolapathology It's incredibly sad when a former fellow and friend passes. Stefan was a deep thinker about cytopathology who wasn't afraid to be provocative. We will miss him.

[Douglas Paul Clark, MD @futurepathology]

@aakasharmand @marthabpitman @mdlozanoe @MauroSaieg @pathologyfinder @Sinchita_Roy Agree, @marthabpitman nailed it! Our job isn't to label slides, it's to be a valued partner in the clinical management of patients!

[Douglas Paul Clark, MD @futurepathology]

An important article revealing labs' hard work and our essential role in controlling the pandemic. And quotes from our superstar micro lab director @KarissaPhD @TriCoreLabs ‘Nobody Sees Us’: Testing-Lab Workers Strain Under Demand https://t.co/TsWgmlPG2h

[Douglas Paul Clark, MD @futurepathology]

#AI will augment pathology! #DeepLearning may assist pathologists with site of origin in neuroendocrine tumors. Proud of my colleagues @UNMPathology including @JHansonPathMD
https://t.co/Fwe54UeI97

[Douglas Paul Clark, MD @futurepathology]

@KarissaPhD @ParasiteGal @Parasite_Power Loa loa? Travel to endemic area?

[Douglas Paul Clark, MD @futurepathology]

It's critical for #pathologists and #laboratorymedicine professionals to help educate our legislators on our value to providers and patients. In #NewMexico we're fortunate to have engaged leaders like @benraylujan

[Douglas Paul Clark, MD @futurepathology]

I invite all #cytopathology friends to join me at #ASCyto19 for New Frontiers: #AI and #pathology Friends or Foes? (Hint: Friends!) Fri., Nov. 15 at 8 AM. Speakers include @TobyCornish Michael Quick and Sylvain Berlemont.

[Douglas Paul Clark, MD @futurepathology]

I was thrilled to attend and support the TriCore team in promoting the evolution of the #ClinPath laboratory. We #pathologists must get out of our labs and ask our clinical partners and payers about their pain points. #BigData can help but only if we address the right problems

[TriCore Laboratories @TriCoreLabs]

TriCore team is thrilled to be a part of Clinical Lab 2.0 Workshop #cl20 #lab20

[Douglas Paul Clark, MD @futurepathology]

I'm very excited to join the team @TriCoreLabs as Chief Medical Officer to help promote #DigitalPathology and #Populationhealth in the #pathology laboratory!